News & Publications
Find our latest news and analysis here. From the daily Newsstand to the Quarterly Journal, we cover the full breadth of intellectual property law.
Written October 19, 2018
The Federal Circuit on October 12, 2018, affirmed a district court decision invalidating Teva’s patents for Copaxone, its best-selling multiple sclerosis drug. Teva Pharm. USA, Inc. v. Sandoz Inc., Fed. Cir., 10/12/18.
On appeal, Teva contended that the district court erred in finding the patents’ claimed 40mg 3x/week dosing regimen obvious, arguing that the district court relied on hindsight and an improper “obvious to try” analysis. The Federal Circuit noted that there are two situations where the “obvious to try” analysis would run afoul of the Supreme Court’s decision in KSR and § 103 – the first when a POSITA would need to experiment with all the variables to arrive at the patented invention, and the second where the prior research only gives general guidance about the technology in the patented invention. Teva’s patents don’t fall into either situation, the Federal Circuit said.
On appeal, Teva contended that the district court erred in finding the patents’ claimed 40mg 3x/week dosing regimen obvious, arguing that the district court relied on hindsight and an improper “obvious to try” analysis. The Federal Circuit noted that there are two situations where the “obvious to try” analysis would run afoul of the Supreme Court’s decision in KSR and § 103 – the first when a POSITA would need to experiment with all the variables to arrive at the patented invention, and the second where the prior research only gives general guidance about the technology in the patented invention. Teva’s patents don’t fall into either situation, the Federal Circuit said.
Broadcast Opportunities
Looking for opportunities to get published? Submit your work to the AIPLA Quarterly Journal or AIPLA Innovate Magazine.
Exhibitor and Sponsorship Opportunities
Highlight your brand at a premier intellectual property law event, webinar, podcast, or in one of our publications.
For rates, availability, or additional details, click here or contact:
Meghan Donohoe
COO
American Intellectual Property Law Association (AIPLA)
T| +1.703.415.1343
E| mdonohoe@aipla.org